FDA approves new drug for the treatment of HER2+ metastatic breast cancer
On June 8, the FDA approved Perjeta (pertuzumab), a new anti-HER2 therapy, to treat patients with HER2+ metastatic breast cancer. According to the FDA, the drug is intended for patients who have not received prior treatment for metastatic breast cancer with an anti-HER2 therapy or chemotherapy and is to be combined with trastuzumab, another anti-HER2 therapy, and docetaxel, a type of chemotherapy. The FDA made its decision based on a single clinical trial involving 808 patients who were randomly assigned to receive Perjeta, trastuzumab, and docetaxel, or trastuzumab, docetaxel and a placebo. Those treated with the combination containing Perjeta had a median progression-free survival (PFS) of 18.5 months, compared to 12.4 months for those receiving the combination containing a placebo. For more information on the drug and the approval, read the FDA press release on Perjeta.
MYTHS VS. TRUTHS
Brush up on your breast cancer myths and truths. Find out if you know more about breast cancer than the American public.
Speak up and out about breast cancer. Say, “I’ll Talk” and commit to a conversation about breast cancer with people you know and care about.